Skip to main content
. Author manuscript; available in PMC: 2014 May 1.
Published in final edited form as: J Mol Med (Berl). 2012 Dec 19;91(5):637–644. doi: 10.1007/s00109-012-0986-9

Fig. 3.

Fig. 3

HIF-1α antagonist YC-1 decreases eosinophilia and allergic inflammatory markers in a C57BL/6 OVA asthma model. a Lung histology demonstrates decreased inflammation in YC-1- treated OVA mice. b Total lung inflammation was decreased in YC-1-treated OVA mice (*P < 0.001, **P < 0.01). c YC-1-treated OVA mice had fewer eosinophils and more macrophages in BAL (*P < 0.001). d BAL IL-5 was lower in YC-1-treated OVA mice (*P < 0.01, **P < 0.05). e OVA-specific IgE levels were no different in YC-1-treated OVA mice compared to controls and OVA mice, while OVA mice had higher levels than controls (*P < 0.05). f Eosinophilia in blood was de- creased in YC-1-treated OVA mice (*P < 0.001) and was no dif- ferent than no-OVA controls. Eight mice were used per experimental group. ELISAs and NO measurements were done in triplicate and repeated once.